{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:02:42Z","timestamp":1791907362563,"version":"4.3.4"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clon.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T13:11:43Z","timestamp":1707225103000},"page":"103523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Quality of Decision Making in Radiation Oncology"],"prefix":"10.1016","volume":"38","author":[{"given":"S.K.","family":"Vinod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Merie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Harden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2024.02.001_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clon.2014.10.005","article-title":"Evidence-based estimates of the demand for radiotherapy","volume":"27","author":"Delaney","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.02.001_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.radonc.2017.11.004","article-title":"The population benefit of evidence-based radiotherapy: 5-year local control and overall survival benefits","volume":"126","author":"Hanna","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.31664","article-title":"Global cancer incidence in older adults, 2012 and 2035: a population-based study","volume":"144","author":"Pilleron","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer","volume":"388","author":"Kunkler","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMoa2302344","article-title":"Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer","volume":"389","author":"Whelan","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review","volume":"134","author":"Murphy","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2008.21.2613","article-title":"Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort","volume":"27","author":"Shappley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clon.2020.06.016","article-title":"Beyond performance status","volume":"32","author":"Simcock","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/j.1532-5415.2005.00506.x","article-title":"Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality","volume":"53","author":"Mitnitski","year":"2005","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.clon.2024.02.001_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"key":"10.1016\/j.clon.2024.02.001_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jgo.2019.04.016","article-title":"A\u00a0systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer","volume":"10","author":"van Walree","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual report to the nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.02.001_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","article-title":"Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers","volume":"20","author":"Fowler","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib23","first-page":"761","article-title":"Geriatric assessment in the management of older patients with cancer; a systematic review (update)","volume":"13","author":"Hamaker","year":"2022","journal-title":"J\u00a0Geriat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib24","article-title":"The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: a systematic review","volume":"14","author":"Disalvo","year":"2023","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib25","doi-asserted-by":"crossref","first-page":"E203","DOI":"10.1016\/j.clon.2020.09.002","article-title":"Impaired Geriatric 8 score is associated with worse survival after radiotherapy in older patients with cancer","volume":"33","author":"Middelburg","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jgo.2019.05.002","article-title":"Prognostic value of two geriatric screening tools in a cohort of older patients with early stage non-small cell lung cancer treated with hypofractionated stereotactic radiotherapy","volume":"11","author":"Cuccia","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canep.2017.11.002","article-title":"Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer","volume":"51","author":"Dunn","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clon.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cncr.33991","article-title":"Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials","volume":"128","author":"Javier-DesLoges","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijrobp.2023.04.006","article-title":"Risk of radiation dermatitis in patients with skin of color who undergo radiation to the breast or chest wall with and without regional nodal irradiation","volume":"117","author":"Purswani","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib33","first-page":"441","article-title":"How useful are international treatment guidelines in low- and middle-income countries?","volume":"3","author":"Kerr","year":"2017","journal-title":"J\u00a0Glob Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib34","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.6004\/jnccn.2014.0068","article-title":"International adaptations of NCCN clinical practice guidelines in oncology","volume":"12","author":"Carlson","year":"2014","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clon.2024.02.001_bib36","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/cncr.32880","article-title":"NCCN resource-stratified and harmonized guidelines: a paradigm for optimizing global cancer care","volume":"126","author":"Koh","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/0971-5851.142040","article-title":"The national cancer grid of India","volume":"35","author":"Pramesh","year":"2014","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077253","article-title":"ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer \u2013 study protocol","author":"Aggarwal","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2024.02.001_bib39","series-title":"Radiotherapy dose and fractionation","author":"The Royal College of Radiologists","year":"2024"},{"key":"10.1016\/j.clon.2024.02.001_bib40","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fonc.2019.01460","article-title":"A\u00a0meta-analysis of the efficacy and toxicity of twice-daily vs. once-daily concurrent chemoradiotherapy for limited-stage small cell lung cancer based on randomized controlled trials","volume":"9","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2022.01.032","article-title":"Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials","volume":"173","author":"Viani","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(97)06305-8","article-title":"Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee","volume":"350","author":"Saunders","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2024.02.001_bib44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clon.2015.02.008","article-title":"Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits","volume":"27","author":"Ray","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib45","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1016\/j.clon.2022.05.019","article-title":"Change in the use of fractionation in radiotherapy used for early breast cancer at the start of the COVID-19 pandemic: a population-based cohort study of older women in England and Wales","volume":"34","author":"Gannon","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.breast.2022.01.018","article-title":"Moderately hypofractionated post-operative radiation therapy for breast cancer: systematic review and meta-analysis of randomized clinical trials","volume":"62","author":"Marta","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.clon.2024.02.001_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib48","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib49","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2024.02.001_bib50","series-title":"Postoperative radiotherapy for breast cancer: hypofractionation RCR consensus statement","author":"Royal College of Radiologists","year":"2021"},{"key":"10.1016\/j.clon.2024.02.001_bib51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.radonc.2020.07.038","article-title":"Variation in the use of radiotherapy fractionation for breast cancer: survival outcome and cost implications","volume":"152","author":"Batumalai","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/tbj.13724","article-title":"Hypofractionated radiation treatment for breast cancer: the time is now","volume":"26","author":"Moran","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.clon.2024.02.001_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.radonc.2020.10.008","article-title":"Hypofractionated radiation therapy for breast cancer: preferences amongst radiation oncologists in Europe - results from an international survey","volume":"155","author":"Ratosa","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib54","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib56","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2024.02.001_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib59","first-page":"Cd011462","article-title":"Hypofractionation for clinically localized prostate cancer","volume":"9","author":"Hickey","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2024.02.001_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijrobp.2021.04.033","article-title":"Population-level uptake of moderately hypofractionated definitive radiation therapy in the treatment of prostate cancer","volume":"111","author":"Nithiyananthan","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.29647","article-title":"Evaluation of hypofractionated radiation therapy use and patient-reported outcomes in men with nonmetastatic prostate cancer in Australia and New Zealand","volume":"4","author":"Pryor","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clon.2024.02.001_bib63","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jamaoncol.2023.4267","article-title":"Increasing use of shorter-course radiotherapy for prostate cancer","volume":"9","author":"Yu","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib64","series-title":"Results of the NPCA prospective audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019. National clinical audit and patient outcomes","author":"Anonymous","year":"2021"},{"key":"10.1016\/j.clon.2024.02.001_bib65","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib66","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypofractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","article-title":"ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases","volume":"173","author":"van der Velden","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2019.06.037","article-title":"Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis","volume":"141","author":"Chow","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2006.02.007","article-title":"Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study","volume":"78","author":"van der Linden","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.radonc.2004.09.017","article-title":"Randomized trial of 8Gy in 1 versus 20Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)","volume":"75","author":"Roos","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib71","first-page":"96","article-title":"International patterns of practice in radiotherapy for bone metastases: a review of the literature","volume":"3","author":"McDonald","year":"2014","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib72","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijrobp.2016.05.016","article-title":"The pattern of use of hypofractionated radiation therapy for early-stage breast cancer in New South Wales, Australia, 2008 to 2012","volume":"96","author":"Delaney","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2021.01.003","article-title":"Hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey","volume":"157","author":"Rodin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/GO.23.00046","article-title":"Hypofractionation adoption in prostate cancer radiotherapy: results of an international survey","author":"Sabbagh","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0167-8140(00)00214-0","article-title":"Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system?","volume":"56","author":"Lievens","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib76","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.prro.2021.08.012","article-title":"One fraction size does not fit all: patient preferences for hypofractionated radiation therapy from a discrete choice experiment","volume":"12","author":"Sigurdson","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008592","article-title":"Promoting professional behaviour change in healthcare: what interventions work, and why? A theory-led overview of systematic reviews","volume":"5","author":"Johnson","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2024.02.001_bib78","series-title":"National Lung Cancer Audit. Spotlight report on curative-intent treatment of stage I\u2013IIIa non-small-cell lung cancer","author":"Royal College of Physicians","year":"2020"},{"key":"10.1016\/j.clon.2024.02.001_bib79","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2015.06.044","article-title":"Impact of using audit data to improve the evidence-based use of single-fraction radiation therapy for bone metastases in British Columbia","volume":"94","author":"Olson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib80","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2024.02.001_bib82","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib84","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.20.01024","article-title":"Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China","volume":"38","author":"Wang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib85","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3\u201307\/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study","volume":"400","author":"Chua","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2024.02.001_bib86","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib87","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib88","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"de Vries","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib89","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamaoncol.2023.0356","article-title":"Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: phase 3 results of NRG Oncology\/RTOG 0631 randomized clinical trial","volume":"9","author":"Ryu","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib90","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib91","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","article-title":"Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy","volume":"128","author":"Sprave","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib92","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib93","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijrobp.2020.11.060","article-title":"Pain response after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases\u2014a phase 2 randomized controlled trial within a prospective cohort","volume":"110","author":"Pielkenrood","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00215","article-title":"The MRI-Linear Accelerator Consortium: evidence-based clinical introduction of an innovation in radiation oncology connecting researchers, methodology, data collection, quality assurance, and technical development","volume":"6","author":"Kerkmeijer","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib95","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.ijrobp.2021.07.330","article-title":"Long-term multi-institutional outcomes of 5-fraction ablative stereotactic MR-guided adaptive radiation therapy (SMART) for inoperable pancreas cancer with median prescribed biologically effective dose of 100 Gy","volume":"111","author":"Chuong","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1151256","article-title":"Outcome of the first 200 patients with prostate cancer treated with MRI-Linac at Assuta MC","volume":"13","author":"Gelbart Pridan","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib97","first-page":"46","article-title":"Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer","volume":"25","author":"Hunt","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib98","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013guided vs computed tomography\u2013guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib99","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2022.07.027","article-title":"MRI-guided radiotherapy (MRgRT) for treatment of oligometastases: review of clinical applications and challenges","volume":"114","author":"Chetty","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.02.001_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.652889","article-title":"Sensible introduction of MR-guided radiotherapy: a warm plea for the RCT","volume":"11","author":"Verkooijen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01328","article-title":"The MOMENTUM Study: an international registry for the evidence-based introduction of MR-guided adaptive therapy","volume":"10","author":"de Mol van Otterloo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13014-022-02033-2","article-title":"MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial","volume":"17","author":"Hoegen","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2021.05.022","article-title":"Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: decision analytic modelling","volume":"161","author":"Hehakaya","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib104","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1754-9485.13021","article-title":"Particle therapy tumour outcomes: an updated systematic review","volume":"64","author":"Hwang","year":"2020","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib105","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.19.02503","article-title":"Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer","volume":"38","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib106","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non\u2013small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib107","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211175","article-title":"Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy","volume":"95","author":"Burnet","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clon.2024.02.001_bib108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clon.2021.09.010","article-title":"A\u00a0novel model and infrastructure for clinical outcomes data collection and their systematic evaluation for UK patients receiving proton beam therapy","volume":"34","author":"Hwang","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib109","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/1754-9485.13557","article-title":"Minimum data elements for the Australian Particle Therapy Clinical Quality Registry","volume":"67","author":"Hwang","year":"2023","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib110","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A\u00a0prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib111","first-page":"147","article-title":"TORPEdO: a phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer","volume":"38","author":"Thomson","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib112","article-title":"Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): initial dosimetric experience","volume":"39","author":"Pedone","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2024.02.001_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070071","article-title":"Investigating survival, quality of life and cognition in PROton versus photon therapy for IDHmutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden","volume":"13","author":"Heggeb\u00f8","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2024.02.001_bib114","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2020.07.056","article-title":"First experience with model-based selection of head and neck cancer patients for proton therapy","volume":"151","author":"Tambas","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:36:53Z","timestamp":1762331813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655524000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":114,"alternative-id":["S0936655524000670"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2024.02.001","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Decision Making in Radiation Oncology","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103523"}}